U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

People who have tried other methods to lose weight have found results from obesity drugs that ‘feel like magic.’ ...

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

Due to current legislation, Medicare Part D or C plans may only cover Zepbound for obstructive sleep apnea. However, the Centers for Medicare & Medicaid Services may expand weight loss medication ...

States that do provide coverage have tried to manage costs by putting prescribing limits on the GLP-1s. There’s also some ...

The Centers for Medicare and Medicaid Services recently announced—without explanation—that it would not proceed with a ...

The US Centers for Medicare & Medicaid Services (CMS) confirmed that it will not proceed with a Biden administration proposal ...

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...

The Centers for Medicare & Medicaid Services (CMS) did not finalize a provision to cover obesity drugs like Eli Lilly's LLY ...